Exclusive Online Content
Ovid Therapeutics Announces Collaboration With Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
Ovid Therapeutics Inc. and Graviton Bioscience Corporation recently announced a collaboration agreement to innovate novel medicines they believe will significantly change….
Tavros Therapeutics & OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform, partnership streamlines drug development for novel cancer therapies….
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown & Long Duration of Effect
Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses….
Radiant Biotherapeutics Emerges From Stealth Mode With $8-Million Seed Round & Two Pharma Partnerships
Radiant Biotherapeutics emerged from stealth mode unveiling an $8-million seed financing and two significant pharmaceutical partnerships. The company, based on foundational IP from….
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia
NewAmsterdam Pharma Company N.V. announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia….
Merck Strengthens Immunology Pipeline With Acquisition of Prometheus Biosciences
Merck and Prometheus Biosciences, Inc. recently announced the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for….
Clearmind Medicine Engages Experienced CRO to Support its First-in-Human Clinical Trial
Clearmind Medicine Inc. recently announced additional preparations to facilitate the commencement of the company’s clinical trial and engaged a contract research organization (CRO) to provide support for….
Roquette Cuts Ribbon on $25-Million Pharmaceutical Innovation Center in the US
Roquette recently celebrated the grand opening of its new Pharmaceutical Innovation Center, located near Philadelphia, PA, right in the heart of the United States’ Northeastern pharmaceutical corridor…..
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
Ajinomoto Bio-Pharma Services recently announce the US FDA has approved the company’s high potency vial line to manufacture a commercial product…..
PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne & San Diego
New equipment added to San Diego and Melbourne facilities will help with clinical scale and global capacity shortages….
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
Tiziana Life Sciences Ltd. recently announced it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 diabetes…..
Lisata Therapeutics & Warpnine Announce First Patient Treated in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma Trial
Lisata Therapeutics, Inc. and Warpnine Incorporated recently announced the treatment of the first patient in the iLSTA Trial of Lisata’s LSTA1 in combination with standard-of-care chemotherapy and….
ProBioGen & ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen and ImmunOs Therapeutics recently announcd the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs’ lead program for the….
Kala Pharmaceuticals Receives FDA Fast Track Designation for Human MSC-S Therapy for Persistent Corneal Epithelial Defect
Kala Pharmaceuticals, Inc. recently announced the US FDA has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of….
Biogen Exercises Option With Denali to Develop & Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Biogen Inc. and Denali Therapeutics Inc. recently announced Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in….
Meridian Medical Technologies Investing $100+ Million in Bridgeton, MO, Expansion
Meridian Medical Technologies recently announced during National Community Development Week it will expand manufacturing capabilities in….
Celanese Announces Agreement With Glaukos Corporation for Sustained-Release Glaucoma Treatment
Celanese Corporation, a global specialty materials and chemical company, recently announced it has entered into an agreement with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for use as….
Bora Pharmaceuticals & Celltrion Partner to Expand OSD Capabilities in APAC Market
Bora Pharmaceuticals Co., Ltd. and Celltrion Asia Pacific Pte., Ltd. recently announced their partnership to contract manufacture and commercialize a range of oral dosage form drugs (OSD) across the APAC region…..
Lonza & ABL Bio Collaborate in the Development & Manufacture of Bispecific Antibody Product
Lonza recently announced it has an agreement with ABL Bio to support the development and manufacturing of ABL Bio’s new bispecific antibody product….
Absci Partners With Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology
Absci Corporation and M2GEN recently announced a partnership to create new cancer medicines and bring them to market at unprecedented speed. Absci’s generative AI drug creation platform will tap into M2GEN’s clinical and….
